LISTING OF THE CLAIMS

This Listing of Claims will replace all prior versions and listings of claims in the above-referenced patent application:

1. (Presently Amended) An intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ comprising:

a) an anti-ulcerative compound having the following formula:



wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

X is a member selected from the group consisting of —O—, —S— or



,

where R^3 is a member selected from the group consisting of hydrogen, lower alkyl, phenyl, benzyl, and lower alkoxycarbonyl; and

Z is selected from the group consisting of:

(1) a group of the formula:

$$-O(CH_2)_p-O-R^4$$

where p is an integer of 1 to 3 and R^4 is a hydrogen atom or a lower alkyl, aryl or aralkyl group;

(2) a group of the general formula:

$$-O(CH_2)_q-R^5$$

where q is an integer of 1 to 3 and R^5 is a halogen atom or an alkoxycarbonyl, aryl or heteroaryl group;

(3) a group of the general formula:

$$-O(CH_2)_r-O(CH_2)_s-R^6$$

where r and s each independently are an integer of 1 to 5 and R^6 is a hydrogen atom or a lower alkyl group;

(4) a group of the formula:  ;

(5) a group of the formula:  ;

(6) a group of the formula: 

(7) a group of the general formula: 

where t is an integer of 0 to 2 and A is a lower alkyl, alkoxycarbonylmethyl, pyridyl or furyl

group, or a group of the general formula: 

where P is selected from the group consisting of: —NH—, —O— or —S—.or a group of the general formula:



wherein R^7 is hydrogen or lower alkyl and w is from 0 to 3;

(8) a group of the general formula:  where R^8 is an

acetoxy or lower alkyl group; and

(9) a group of the general formula: $-OR^9$

where R^9 is a hydrogen atom or a lower alkyl or aryl group;

n is an integer of 0 to 2; m is an integer of 2 to 10, and

J and K are independently hydrogen or lower alkyl, with the proviso that when Z is a group falling under the above category (9), R^9 is a lower alkyl group and m stands for an integer of 3 to 10, and pharmaceutically acceptable salts thereof; ~~and~~

b) glycine~~, in a pharmaceutically acceptable carrier.~~;

c) NaOH;

d) a solution with a pH between about 10 and 11; and

e) a tonicity agent;

wherein the glycine is present in an amount sufficient to prevent the intravenous aqueous pharmaceutical formulation from turning yellow.

2. (Presently Amended) ~~An~~ The intravenous aqueous pharmaceutical formulation of claim 1, ~~suitable for intravenous injection~~ comprising:

a) an anti-ulcerative compound having the following formula:



wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

wherein R^9 is selected from the group consisting of hydrogen, lower alkyl, and aryl;

wherein J is selected from the group consisting of hydrogen or lower alkyl;

wherein m is an integer from 2 to 10;

and pharmaceutically acceptable salts thereof; ~~and~~

b) glycine~~, in a pharmaceutically acceptable carrier.~~;

c) NaOH;

d) a solution with a pH between about 10 and 11; and

e) a tonicity agent;

wherein the glycine is present in an amount sufficient to prevent the intravenous aqueous pharmaceutical formulation from turning yellow.

3. (Presently Amended) ~~An~~ The intravenous aqueous pharmaceutical formulation of claim 1, ~~suitable for intravenous injection~~ comprising:

a) an anti-ulcerative compound having the following formula:



wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

wherein R^4 is selected from the group consisting of hydrogen, lower alkyl, aryl, and aralkyl;

wherein J is selected from the group consisting of hydrogen or lower alkyl;

wherein m is an integer from 2 to 10;

wherein p is an integer from 1 to 3;

and pharmaceutically acceptable salts thereof; ~~and~~

b) glycine~~, in a pharmaceutically acceptable carrier.~~;

c) NaOH;

d) a solution with a pH between about 10 and 11; and

e) a tonicity agent;

wherein the glycine is present in an amount sufficient to prevent the intravenous aqueous pharmaceutical formulation from turning yellow.

4. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 1, ~~further comprising a~~ wherein the tonicity agent is

selected from the group consisting of sodium chloride, glycerin, mannitol, sucrose, lactose, and dextrose.

5. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 2, wherein ~~said~~ the tonicity agent is selected from the group consisting of sodium chloride and dextrose.

6. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 3, wherein ~~said~~ the tonicity agent is selected from the group consisting of sodium chloride and dextrose.

7. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 1, wherein ~~said~~ the compound is



8. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 7, wherein ~~said~~ the tonicity agent is selected from the group consisting of sodium chloride and dextrose.

9. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 8, wherein ~~said~~ the tonicity agent is sodium chloride

and ~~said~~ the sodium chloride is present in ~~said~~ the formulation at a concentration of about 0.9% by weight.

10. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 8, wherein ~~said~~ the tonicity agent is dextrose and ~~said~~ the dextrose is present in ~~said~~ the formulation at a concentration of about 5% by weight.

11. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 1, wherein ~~said formulation has an alkaline pH, and wherein~~ ~~said~~ the glycine in ~~said~~ the formulation is present at a concentration of between about 1 mM and 300 mM.

12. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 4 wherein ~~said formulation has a pH of between about 9 and about 12, and wherein said~~ the glycine in ~~said~~ the formulation is present at a concentration of between about 10 mM and 300 mM.

13. (Presently Amended) The intravenous aqueous pharmaceutical formulation ~~suitable for intravenous injection~~ of claim 8, wherein ~~said formulation has a pH of between about 9 and 12, and wherein said~~ the glycine in ~~said~~ the formulation is present at a concentration of between about 10 mM and 300 mM.

14. (Presently Amended) A method for stabilizing anti-ulcerative intravenous formulations ~~suitable for intravenous injection~~ which comprises:

a) providing a compound of the formula



wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

X is a member selected from the group consisting of –O–, –S– or  ,

where R^3 is a member selected from the group consisting of hydrogen, lower alkyl, phenyl, benzyl, and lower alkoxycarbonyl; and

Z is selected from the group consisting of:

(1) a group of the formula:

$$-O(CH_2)_p-O-R^4$$

where p is an integer of 1 to 3 and R^4 is a hydrogen atom or a lower alkyl, aryl or aralkyl group;

(2) a group of the general formula:

$$-O(CH_2)_q-R^5$$

where q is an integer of 1 to 3 and R^5 is a halogen atom or an alkoxycarbonyl, aryl or heteroaryl group;

(3) a group of the general formula:

$$-O(CH_2)_r-O(CH_2)_s-R^6$$

where r and s each independently are an integer of 1 to 5 and R^6 is a hydrogen atom or a lower alkyl group;

(4) a group of the formula:  ;

(5) a group of the formula:  ;

(6) a group of the formula:  ;

(7) a group of the general formula:  ;

where t is an integer of 0 to 2 and A is a lower alkyl, alkoxycarbonylmethyl, pyridyl or furyl

group, or a group of the general formula: 

;

where P is selected from the group consisting of: —NH—, —O— or —S— or a group of the general formula:



,

wherein R^7 is hydrogen or lower alkyl and w is from 0 to 3;

(8) a group of the general formula: 

where R^8 is an acetoxy or lower alkyl group; and

(9) a group of the general formula: —OR^9

where R^9 is a hydrogen atom or a lower alkyl or aryl group;

n is an integer of 0 to 2; m is an integer of 2 to 10, and

J and K are independently hydrogen or lower alkyl, with the proviso that when Z is a group falling under the above category (9), R^9 is a lower alkyl group and m stands for an integer of 3 to 10, and pharmaceutically acceptable salts thereof;

b) providing ~~a~~ an intravenous aqueous solution ~~suitable for intravenous injection~~ which has a pH of between about 10 and 11 and which comprises glycine; ~~and~~

c) admixing ~~said~~ the compound and ~~said~~ the solution until ~~said~~ the compound is dissolved in ~~said~~ the solution~~.~~;

wherein the glycine is present in an amount sufficient to prevent the intravenous aqueous pharmaceutical formulation from turning yellow.

15. (Presently Amended) The method of claim 14, wherein ~~said~~ the solution contains a solute selected from the group consisting of dextrose and sodium chloride.

16. (Presently Amended) The method of claim 14, wherein ~~said~~ the glycine is present in ~~said~~ the solution at a concentration of between about 10 and about 300 mM.

17. (Presently Amended) The method of claim 14, wherein ~~said~~ the compound is



18. (Presently Amended) The method of claim 17, wherein ~~said~~ the solution contains a solute selected from the group consisting of dextrose and sodium chloride.

19. (Presently Amended) The method of claim 18, wherein ~~said~~ the glycine is present in ~~said~~ the solution at a concentration of between about 10 and about 300 mM.

20. (Presently Amended) The method of claim 19, wherein ~~said~~ the solution contains a solute selected from the group consisting of dextrose and sodium chloride, and wherein ~~said~~ the solution is isotonic with blood plasma.

21. (Cancelled) The formulation of claim 1, which comprises a tonicity agent.

22. (Cancelled) The formulation of claim 1, which comprises sodium hydroxide.

23. (Cancelled) The pharmaceutical formulation of claim 11, wherein said alkaline pH is between about 9 and about 12.